薬剤学および薬物送達研究ジャーナル

Population Pharmacokinetics of Lixisenatide, a Once-Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Thomas Frank

Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Lixisenatide is a potent and selective glucagon-like peptide-1(GLP-1) receptor agonist developed for the treatment of type 2 diabetes (T2DM) with a subcutaneous once-daily regimen. The substance is currently under review for marketing authorization for the management of T2DM. In this study, the population pharmacokinetics in healthy volunteers and in adult T2DM patients was investigated.